
OKLAHOMA CITY, OK – Senator James Lankford (R-OK) joined Senator Cindy Hyde-Smith (R-MS) and 125 of their colleagues to demand the Food and Drug Administration (FDA) immediately restore more stringent oversight of chemical abortion pills, including the in-person dispensing requirement the FDA suspended in December.
They sent a letter to FDA Commissioner Dr. Robert Califf that cites studies that affirm the increased health risks to women who use the chemical abortion drug mifepristone. In December the FDA removed in-person dispensing requirements from the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, clearing the way for widespread mail-order distribution of the drug.
The letter cites research showing the increased serious risks associated with mifepristone, including a first-of-its-kind longitudinal study, published in November 2021 that found the rate of abortion-related emergency room visits following a chemical abortion increased by more than 500 percent from 2002 through 2015.
Lankford has been the leading voice in Congress for the protection of life. …
You can read the letter HERE.